Genentech's susvimo maintains vision over five years with two refills per year in people with wet age-related macular degeneration (amd)

South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), announced today new, five-year efficacy, safety and durability data from the phase iii portal study, a long-term extension of the phase iii archway study, of susvimo® (ranibizumab injection) for the treatment of people with wet amd. results show that susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment ev.
AMD Ratings Summary
AMD Quant Ranking